The efficacy of an HIV vaccine to prevent infection is likely to depend on the genetic variation of the exposing virus. This paper addresses the problem of using data on the HIV sequences that infect vaccine efficacy trial participants to (1) test for vaccine efficacy more powerfully than procedures that ignore the sequence data and (2) evaluate the dependence of vaccine efficacy on the divergence of infecting HIV strains from the HIV strain that is contained in the vaccine. Because hundreds of amino acid sites in each HIV genome are sequenced, it is natural to treat the genetic divergence as a continuous mark variable that accompanies each failure (infection) time. Problems (1) and (2) can then be approached by testing whether the ratio of the mark-specific hazard functions for the vaccine and placebo groups is unity or independent of the mark. We develop nonparametric and semiparametric tests for these null hypotheses and nonparametric techniques for estimating the mark-specific relative risks. The asymptotic properties of the procedures are established. In addition, the methods are studied in simulations and are applied to HIV genetic sequence data collected in the first HIV vaccine efficacy trial.
INTRODUCTION
Competing risks failure time data consist of survival times and a mark variable that describes a feature of the failure. Often such data are available for 2 treatment groups, and it is of interest to account for this mark in comparing the failure experience. In this article, we develop procedures to assess continuous mark-specific relative risks. This departs from our recent work (Gilbert and others, 2004) in which we developed a test for the dependence of a single continuous mark-specific hazard rate on the mark variable (i.e. the "1-sample" problem). We expand the scope of research to include estimation as well as testing and semiparametric as well as nonparametric hypothesis testing.
We are motivated by applications in preventive HIV vaccine efficacy trials. The extensive genetic diversity of HIV poses one of the greatest challenges to developing an AIDS vaccine. Vaccine efficacy to prevent infection, usually defined in terms of the hazard ratio between vaccine and placebo recipients, may decrease with the viral genetic sequence divergence of a challenge HIV from the virus or viruses represented in the vaccine construct (Gilbert and others, 1999) . Detecting that the vaccine protects against some strains but not others, and quantifying the relationship between vaccine efficacy and viral divergence, is useful for guiding vaccine deployment decisions and for designing new vaccines that provide greater breadth of protection.
From 1998 to 2003, VaxGen Inc. conducted the first HIV vaccine efficacy trial (Flynn and others, 2005) . HIV-uninfected volunteers at high risk for acquiring HIV were randomized to receive the vaccine AIDSVAX (n 1 = 3598) or placebo (n 2 = 1805). Subjects were monitored for 3 years for the primary study end point HIV infection. For each subject who became HIV infected, the envelope glycoprotein (gp120) region of the infecting virus was sequenced. Of the 368 subjects who acquired HIV, the sequence data were collected for 336 subjects (217 of 241 vaccine and 119 of 127 placebo). VaxGen hypothesized that the level of vaccine efficacy would be higher against HIVs with gp120 amino acid sequences that were relatively similar to either of the 2 HIV strains (named MN and GNE8) that were represented in the vaccine. The distance of each infecting virus to MN and GNE8 was measured by the percent mismatch in the aligned amino acid sequences (i.e. Hamming distance) for 3 sets of positions hypothesized to be important for neutralizing HIV (Wyatt and others, 1998) : (1) the neutralizing face core of gp120 that was crystalized, (2) the neutralizing face core plus the variable loop V2/V3 regions, and (3) the V3 loop. For each metric and infecting virus, the mark is defined as the minimum of the 2 distances to the MN and GNE8 reference sequences. Gilbert and others (1999) and Gilbert (2000) developed a semiparametric biased sampling model as a tool for studying vaccine efficacy as a function of a continuous mark. This model parametrically specifies the relationship between the vaccine efficacy and the mark and leaves the distribution of the mark in the infected placebo group unspecified. However, there are no data available for suggesting the correct parametric model, so nonparametric methods are desirable. Furthermore, the earlier work is limited by conditioning on infection, so odds ratios but not relative risks of infection can be estimated, and the model treats HIV infection as a binary outcome, ignoring the time to HIV infection. The methods presented here were developed because they are free from these limitations, as they are non-or semi-parametric, are prospective, and incorporate the failure times.
We introduce tests for the hypothesis that the continuous mark-specific risks in the 2 groups coincide and for the hypothesis that the relative mark-specific risk between the groups is independent of the mark. Let T k be the time to end point and V k be the mark variable for a representative individual in group k (in vaccine trials, k = 1 indicates vaccine and k = 2 indicates placebo). In the study, we observe
, and C k is a censoring time assumed to be independent of both T k and V k , k = 1, 2. The notation δ k V k indicates that the mark V k is only observed if the failure time is observed (δ k = 1); if δ k = 0, V k is undefined and not relevant. We assume that V k has known and bounded support; rescaling V k if necessary, this support is taken to be [0, 1] . The mark-specific hazard rate in group k is
and the mark-specific cumulative incidence function is
2) k = 1, 2, with t ranging over a fixed interval [0, τ ] . These functions are natural extensions of the cause-specific hazard function and cumulative incidence function that have been extensively studied for a discrete mark variable (e.g. Prentice and others, 1978) . Similar to the discrete mark case, the functions (1.1) and (1.2) are related by the equation
is the survival function for group k, and are estimable from the observed group k competing risks failure time data.
A standard measure of vaccine efficacy to prevent infection at time t is the relative reduction in hazard due to vaccination: VE(t) = 1 − λ 1 (t)/λ 2 (t), see Halloran and others (1997) . It is natural to extend this definition to allow the vaccine efficacy to depend on viral divergence: VE(t, v) = 1 − λ 1 (t, v)/λ 2 (t, v). To interpret VE(t, v), consider that λ k (t, v) aggregates many parameters that are not identifiable due to the absence of data on sexual and needle contacts. These parameters include (i) the participant distribution of per-contact susceptibility to strain v, (ii) the distribution of infectiousness of contacts infected with strain v, (iii) the mechanism of vaccine protection (Halloran and others, 1992) , (iv) the density of V at v in the population of HIV-infected contacts, and (v) the participant distribution of contact rates. Despite these complicating factors, randomization, double blinding, and the fact that HIV infection is a rare event in HIV vaccine efficacy trials imply that VE(t, v) should approximately measure the vaccine effect to reduce susceptibility to HIV acquisition given exposure to strain v at time t. Strong assumptions about the parameters in (i)-(v) confer specific meaningful interpretations to VE(t, v), as explored in the supplementary material available at Biostatistics online.
The VE(t) and VE(t, v) measures must be used with care given that they do not account for the network structure of sexual and/or needle contacts. Alternative concepts of VE could be considered that explicitly consider this structure and incorporate individual-level models of vaccine response.
To account for the mark in testing for vaccine efficacy, we develop tests for
against the following alternative hypotheses:
with strict inequality for some
Testing H 0 0 evaluates VE(t, v) = 0 for all t and v, that is, whether there is any vaccine efficacy against any HIV strain. As we show in simulations, tests of H 0 0 can have much greater power than standard tests of vaccine efficacy that ignore the mark, that is, that evaluate the null hypothesis λ 1 (t) = λ 2 (t) for all t ∈ [0, τ ]. A test ignoring the mark should be done in conjunction with a test of H 0 0 , however, to assess the overall clinical/public health benefit of the vaccine. To illustrate the importance of carrying out both tests, if VE(t) = 0 and VE(t, v) is positive (negative) for v (>) 0.5, then the vaccine clearly should not be declared effective. Yet, the analysis accounting for the mark would lead to follow-up studies of the mechanism by which the vaccine impacted mark-specific infection risk.
If H 0 0 is rejected, then it is of interest to assess if vaccine efficacy varies with strain distance. Accordingly, we also develop tests for
with strict inequality for some t, v 1 , v 2 in H 1 . Because H 0 and H 1 can be reexpressed as H 0 : VE(t, v) = VE(t) for all t, v and H 1 : VE(t, v 1 ) VE(t, v 2 ) for all t, v 1 v 2 (with < for some v 1 > v 2 ), testing H 0 versus H 1 assesses whether vaccine efficacy decreases with HIV sequence divergence. Scientifically, this is of particular interest to assess.
To develop test statistics for evaluating H 0 , we will exploit the observation that H 0 holds if and only if the mark-specific relative risk coincides with the ordinary relative risk, that is,
dv is the group-k hazard irrespective of the mark. As for discrete competing risks, the density of the mark makes no contribution to the total hazard other than through the mark-specific hazard, which represents the hazard rate accounting for the density of a specific strain. In Section 2, we introduce the proposed procedures for testing H 0 0 and H 0 . Large-sample results and a simulation technique needed to implement the test procedures are summarized in Section 3. In Section 4, we discuss nonparametric estimation of the mark-specific vaccine efficacy. We summarize the results of a simulation experiment in Section 5, and an application to data from the VaxGen trial is provided in Section 6. Section 7 contains concluding remarks. The supplementary material available at Biostatistics online (http://www.biostatistics.oxfordjournals.org) contains expanded details on the interpretation of VE(t, v) (Section A), details of the large-sample results and Gaussian multipliers simulation technique for estimating critical values (Section B), expanded simulation results (Section C), and proofs of the large-sample results (Section D).
TEST PROCEDURE
We base our approach on estimates of the doubly cumulative mark-specific hazard functions
where
is the size of the risk set for group k at time t, and
is the marked counting process with jumps at the uncensored failure times X ki and associated marks V ki , see Huang and Louis (1998, (3. 2)). Our tests of H 0 0 are based on comparingˆ 1 (t, v) andˆ 2 (t, v) and of H 0 are based on comparing the nonparametric MLE of 1 (t, v) − 2 (t, v) with an estimate under H 0 . Since H 0 is equivalent to 1 
is a nonparametric estimator of λ k (t), as discussed below. Alternatively, under a proportional marginal hazards assumption, λ 1 (t)/λ 2 (t) = exp(β), this difference may be estimated by
, whereβ is the maximum partial likelihood estimator of β, which leads to a semiparametric test for H 0 . The nonparametric approach makes minimal assumptions but requires smoothing over time, whereas the semiparametric approach avoids smoothing and in principle may provide greater power when the proportional hazards assumption holds.
For the nonparametric approach, we estimate each hazard function λ k (t) by kernel smoothing: 
Test processes and test statistics
Based on the above discussion, we introduce test processes of the form
is a suitable weight process converging to a nonrandom function H (·) and a 0. The process H n (·) may be used to upweight regions with less variability, improving power, or for other reasons considered in Sections 3.2 and B.3 of the supplementary material available at Biostatistics online.
The superscript r reflects the choice of processr (s) in the test process and indicates whether it is used to test H 0 0 (indicated by r as 1, corresponding tor (s) = 1), to test H 0 nonparametrically (indicated by r as np;r (s) =λ 1 (s)/λ 2 (s)) or to test H 0 semiparametrically (indicated by r as sp;r (s) = exp(β)). A simple calculation shows that for r as np, [·] in (2.3) comparesˆ 1 (ds, v)−ˆ 2 (ds, v) to the nonparametric estimate of 1 (ds, v) − 2 (ds, v) under H 0 described above. The parallel result holds for r as sp using the semiparametric estimate of 1 (ds, v) − 2 (ds, v) under H 0 .
A variety of test statistics can be formulated as functionals of L r n (t, v). We develop integration-type and supremum-type statistics. With w V (v) a known nonnegative weight function, large values of the following statistics provide evidence against H 0 0 in the direction of H 1 0 (first 2 statistics) or H 2 0 (second 2 statistics):
For testing H 0 , let y k (t) = P(X k t), letτ = sup{t : y 1 (t) > 0 and y 2 (t) > 0}, and assume τ <τ . To simplify the proofs and the conditions on the rates of convergence concerning b k , we take a > 0 and construct the test statistics from the process L r n (t, v) over a t τ, 0 v 1. In practice, however, there would be no harm in taking a = 0 in order to use as much of the data as possible (this is done in the simulations and application). 
To motivate the statisticsÛ r 1 andÛ r 2 , we note from the proof of Theorem 2 that (n/n
Under H 1 and some smoothness conditions,
Therefore, large values ofÛ r 1 (Û r 2 ) provide evidence against H 0 in the direction of H 1 (H 2 ).
In Section 3, we provide results that all 3 processes L r n (t, v) (indexed by r ) converge weakly to a Gaussian process under the appropriate null hypothesis. We also state results on the consistency of the proposed tests against their alternatives and summarize a simulation procedure for determining the critical values of theÛ r j .
LARGE-SAMPLE RESULTS
We summarize the asymptotic results with theorems and proofs relegated to the supplementary material available at Biostatistics online. Theorem 1 gives regularity conditions under which L r n (t, v) defined in (2.3) converges weakly to a process L r (t, v) under H 0 as n → ∞.
Let U r j be defined the same asÛ r j in (2.6) and (2.7), with L r n (t, v) replaced with L r (t, v) . 
Gaussian multipliers simulation procedure
We now summarize a Gaussian multipliers technique for simulating each of the test processes L v) , and L 1 n (t, v) under the null hypothesis, cf. Lin and others (1993) . Section B of the supplementary material available at Biostatistics online describes a process 
Choice of weight process
The test process is more variable at larger failure times, so it is advisable to choose the weight process to downweight the upper tail of the integral, and we suggest
The test can be made invariant to the order of the 2 groups by includingr (s) −1/2 in H n (s). The weight H n (s) can also be chosen to increase power against specific alternatives (Sun, 2001 ).
ESTIMATION OF MARK-SPECIFIC VACCINE EFFICACY
Precise estimation of VE(t, v) introduced in Section 1 requires huge sample sizes because smoothing is required in both v and t, and generally efficacy trials do not provide sufficient samples (Gilbert and others, 2002) . Accordingly, we consider an alternative notion of mark-specific vaccine efficacy defined in terms of cumulative incidences:
which we call cumulative vaccine efficacy. This represents a time-averaged -rather than instantaneous -measure of vaccine efficacy and is much easier to estimate than VE(t, v). We also consider the doubly cumulative vaccine efficacy
which can be estimated without any smoothing and with greater precision than VE c (t, v).
A nonparametric estimator of VE c (t, v) is given by VE
is a bounded symmetric kernel function with support [−1, 1] and integral 1, and b k > 0 is a bandwidth. The estimatorF k (t, v) is the continuous analog of the estimator that has been used for a discrete mark (Prentice and others, 1978) . If F 1 (t, v) = 0 and F 2 (t, v) = 0, a 100(1 − α)% pointwise confidence interval for VE c (t, v) can be computed by transforming symmetric confidence limits about log(F 1 (t, v)/F 2 (t, v)): (ds, v) , the standard estimator for the discrete cumulative incidence function for cause of failure defined by V v, and its variance is estimated by
SIMULATION EXPERIMENT
The simulations are based on the features of the VaxGen trial described in Section 1. We study performance of the test statisticsÛ 1 j , j = 1, 2, 3, 4;Û np j andÛ sp j , j = 1, 2; and of VE c (τ, v) , with τ = 3 years. We focus on the case that the mark-specific hazard function factors as λ k (t, v) = λ k (t)c k (v). Limited simulations under more complicated models showed comparable performance of the procedures (see supplementary Table 1 available at Biostatistics online). Under the factorization, the cumulative incidence function for group k is F k (t, v) = P{T k t}c k (v). In the first set of simulations, we specify T 1 and T 2 to be exponential with parameters θλ 2 and λ 2 , respectively, so that the cumulative vaccine efficacy by time τ irrespective of the mark V is given by VE c (τ ) = 1 − (1 − exp(−λ 2 θτ ))/(1 − exp(−λ 2 τ )), where λ 2 is the constant infection hazard rate in the placebo group. Here, θ is the constant infection hazard ratio between groups 1 and 2. In the second set of simulations, we specify non-proportional hazards λ 1 (t) and λ 2 (t) to examine the effect of violating the assumption used by the semiparametric tests of H 0 . In this case, λ 2 (t) = λ 2 as above and T 1 is distributed as Weibull with λ 1 (t) = 2λ 1 t. We select λ 2 so that 50% of placebo recipients are expected to be infected by τ = 36 months, and consider VE c (τ ) = 0.0, 0.33, and 0.67. Next, we specify
The cumulative vaccine efficacy is given by Note that VE(τ, v) = VE(τ ) and VE c (τ, v) = VE c (τ ) if and only if β 1 = β 2 so that setting β 2 /β 1 = 1.0 represents H 0 . Furthermore, β 2 /β 1 > 1 implies VE(τ, v) and VE c (τ, v) decrease with v, and the extent of departure from H 0 increases with β 2 /β 1 . We also consider a 2-sided alternative with c 2 (v) = 1 and
The weight process H n (·) of (3.2) is used for the test statistics andŵ V (·) = 1 forÛ 1 2 andÛ 1 4 . For kernel estimation of λ k (t), k = 1, 2, the Epanechnikov kernel K (x) = 0.75(1−x 2 )I (|x| 1) is used. For each simulation iteration, the optimal bandwidth b k is chosen to minimize an asymptotic approximation to the mean integrated squared error ofλ k (Andersen and others, 1993, p 240 ) separately for k = 1, 2 and the method of Gasser and Müller (1979) is used to correct for bias in the tails.
The nominal level of the tests is set at 0.05, and critical values are calculated using 500 replicates of the Gaussian multipliers technique summarized in Section 3.2. We choose n = 100, 200, or 400, and in addition to the 50% administrative censoring for the failure times at 36 months, we use a 10% random censoring rate in each arm. The performance statistics are calculated based on 1000 simulated data sets.
The results in Table 1 indicate that the tests of H 0 0 have appropriate sizes and high powers. When VE(t, v) declines with v, they have greater power than the Cox model Wald test of VE(t) = 0. Therefore, accounting for the mark variable can substantially improve efficiency. This is especially the case forÛ 1 2 although this test has less power than the Cox model test if VE(t, v) is constant in v (i.e. β 1 = β 2 ). In contrast, the power ofÛ 1 1 is less sensitive to how strongly VE(t, v) varies in v. The corresponding 2-sided testsÛ 1 3 andÛ 1 4 show a similar comparative pattern but with lower power for the 1-sided alternatives. The results in Table 2 show that the tests of H 0 perform well at moderate sample sizes. Somewhat surprisingly, for small/moderate samples, the semiparametric tests did not provide greater power than the nonparametric tests in the case that the failure times had proportional hazards. To explain this, note that the nonparametric and semiparametric test processes involve contrastsˆ 1 (dt, v) −r (t)ˆ 2 (dt, v), withr (t) =λ 1 (t)/λ 2 (t) and exp(β), respectively, and the alternative hypothesis involves changes of 
approximately "track" each other in t, the nonparametric test process can reduce the noise from perturbations ofλ 1 (t)/λ 2 (t) in t, whereas the semiparametric test process cannot dampen this noise. The small simulation study under non-proportional hazards, with H 0 true with (β 1 , β 2 ) = (1.0, 1.0), (0.5, 0.5), or (0.25, 0.25) , demonstrates (as predicted from the theory) that the semiparametric tests are not valid when the marginal proportional hazards condition is not met. The empirical sizes of the tests frequently missed 0.05 by an amount more than 2 or 3 Monte Carlo standard deviations (see supplementary Table 2 available at Biostatistics online). Finally, the point and interval estimators of VE c (36, v) performed well, with details given in Section C of the supplementary material available at Biostatistics online.
APPLICATION
We apply the methods to the data from the VaxGen trial described in Section 1. The 32 infected subjects with a missing HIV sequence (and hence a missing mark) were excluded from the analysis. Figure 1 shows box plots of the 3 amino acid percent mismatch distances of the infecting HIV viruses to the nearest virus (MN or GNE8) represented in the tested vaccine. The testing procedures were implemented using the same weight functions H n (·) and w V (·), kernel K (·), and procedures for optimal bandwidth selection and tail correction that were used in the simulations. The p-values were approximated using 10 000 Monte Carlo simulations. The mean integrated squared error-optimized bandwidths b k for the estimated hazards of infectionλ 1 (·) andλ 2 (·) were b 1 = 1.83 months and b 2 = 2.10 months. For the neutralizing face core distances, the 4 tests of H 0 0 : VE(t, v) = 0 gave p-values spanning 0.05 to 0.32 (Figure 1(d) ), withÛ 1 2 rejecting H 0 0 at the level 0.05. Based on this evidence (albeit weak) that VE(t, v) = 0, we go on to test H 0 : VE(t, v) = VE(t). Neither nonparametric test rejected H 0 (Figure 1(d) ). The proportional hazards assumption seemed reasonable based on a goodness-of-fit test ( p = 0.35), justifying the semiparametric tests of H 0 , which gave nonsignificant results (Figure 1(d) ). To illustrate the graphical procedure, Figure 2 shows the test process L np n (t, v) together with 8 randomly selected realizations of the null test process L np * n (t, v), using a unit weight process H n (·) = 1. The maximum absolute deviation of L np n (t, v) in t is larger than that for all but one of the null test processes. Figure 1 (e) and (f) shows p-values of the tests for the other 2 distances, which all exceeded 0.05.
With bandwidths b v1 and b v2 separately optimized using 2-fold cross-validation, we next estimated VE c (36, v) and VE dc (36, v) (Figure 3) . The VE c (36, v) curves are estimated with reasonable precision at mark values v not in the tail regions, and VE dc (36, v) is estimated with reasonable precision for v not in the left tail, with precision increasing with v. For neutralizing face core distances, the estimates of VE c (36, v) and VE dc (36, v) in the regions of precision diminished with viral distance, suggesting that the closeness of match of amino acids in the exposing strain versus vaccine strain in the core amino acids may have impacted the ability of the vaccine to stimulate protective antibodies that neutralized the exposing strain. This nonsignificant trend is intriguing because this distance has the soundest biological rationale-3-dimensional structural analysis has demonstrated that the amino acid positions used for this distance constitute conserved neutralizing antibody epitopes (Wyatt and others, 1998) .
CONCLUDING REMARKS
Nonparametric and semiparametric methods have been developed for testing and estimation of relative risks taking into account a continuous mark variable observed only at uncensored failure times and for evaluating the relationship between the relative risk and the mark. We showed that if the mark-specific relative risk varies with the mark, then a standard Cox model test of a unit hazard ratio (ignoring the mark) is less powerful (and sometimes much less) than the newly developed nonparametric procedures that test the null hypothesis H 0 0 : λ 1 (t, v)/λ 2 (t, v) = 1 of a unit mark-specific hazard ratio. This finding raises the novel idea to consider accounting for the mark variable in secondary hypothesis tests in clinical trials for which there are strong reasons to suspect that the mark-specific relative risk varies in the mark. Among the statistics developed for testing H 0 0 , we recommendÛ 1 2 if the mark-specific relative risk is thought to vary strongly with the mark, andÛ 1 1 otherwise. For testing dependency of the mark-specific relative risk on the mark, H 0 : λ 1 (t, v)/λ 2 (t, v) = λ 1 (t)/ λ 2 (t), the simulations suggest that the nonparametric procedures perform better than their semiparametric counterparts that assume proportional marginal hazards. The test based onÛ np 1 is recommended. The results also suggest that at least 100-200 failure events in the control group are needed to achieve high power to detect moderate departures from H 0 . Furthermore, to achieve high power it is necessary that the trial population is highly exposed to HIV and the exposing HIVs have wide variation in mark values. As such a consideration for trial design is selecting sites with broad pathogen sequence diversity, which can increase generalizability of the trial results as well as conferring greater power for testing H 0 0 and H 0 . Although the methods were motivated by a particular scientific problem (the question in HIV vaccine efficacy trials of if and how efficacy of the tested vaccine varies with the genetic distance of the infecting HIV strain), we emphasize that they provide a general solution to the 2-sample survival analysis problem with a continuous mark variable, which may have many applications. An appeal of the procedures developed here is that they are based on a mark-specific version of the widely applied and wellunderstood Nelson-Aalen-type nonparametric MLE and naturally extend the scope of methods that have been developed for competing risks data with discrete (cause-of-failure) marks. Code for implementing the procedures is available upon request.
